©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2020; 12(8): 791-807
Published online Aug 15, 2020. doi: 10.4251/wjgo.v12.i8.791
Published online Aug 15, 2020. doi: 10.4251/wjgo.v12.i8.791
Gastrointestinal neuroendocrine tumors in 2020
Monjur Ahmed, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, United States
Author contributions: Ahmed M finished the manuscript alone.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Corresponding author: Monjur Ahmed, FACG, FACP, FASGE, FRCP, MD, Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, 132 South 10th Street, Main Building, Suite 468, Philadelphia, PA 19107, United States. monjur.ahmed@jefferson.edu
Received: December 31, 2019
Peer-review started: December 31, 2019
First decision: April 29, 2020
Revised: May 26, 2020
Accepted: July 18, 2020
Article in press: July 18, 2020
Published online: August 15, 2020
Processing time: 224 Days and 9.5 Hours
Peer-review started: December 31, 2019
First decision: April 29, 2020
Revised: May 26, 2020
Accepted: July 18, 2020
Article in press: July 18, 2020
Published online: August 15, 2020
Processing time: 224 Days and 9.5 Hours
Core Tip
Core tip: Neuroendocrine tumors are increasingly being seen in our clinical practice. There has been excellent progress in the understanding of tumor biology. Currently, we have various ways of diagnosing and treating neuroendocrine tumors. This article will discuss the epidemiology, pathogenesis and clinical aspects as well as the current treatment protocol and follow up recommendations in patients with neuroendocrine tumors.